WHO ICTRP trial
An Open-label Single-arm Pharmacokinetic Trial, Investigating the Effect of…
NL-OMON49212 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON49212 |
|---|---|
| Public title | An Open-label Single-arm Pharmacokinetic Trial, Investigating the Effect of CYP3A4 inhibitor Ritonavir on the Pharmacokinetics of Erlotinib |
| Scientific title | An Open-label Single-arm Pharmacokinetic Trial, Investigating the Effect of CYP3A4 inhibitor Ritonavir on the Pharmacokinetics of Erlotinib - Pharmacokinetics of Erlotinib Plus Ritonavir |
| Primary sponsor | Antoni van Leeuwenhoek Ziekenhuis |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | The Netherlands |
| Conditions | lung cancer ono-small cell lung cancer;10038666;lung cancer;ono-small cell lung cancer |
| Interventions | All subjects will receive erlotinib 75mg for 14 days. From 7 days, this will be combination with ritonavir for CYP3A4 inhibition. ;CYP3A4;Erlotinib;Pharmacokinetics;Ritonavir |
| Registration date | May 28, 2020 |
| Target size | 10 |
| Secondary IDs | 2018-004854-12 ;N19RER;NL68511.031.19 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: